Categories
News

Predictmedix Is Partnering With McGill Researchers for Clinical Research

TORONTO, ON / ACCESSWIRE / November 10, 2020 Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce that the company is partnering with the research group led by Dr. Samira Rahimi for clinical research. Professor Rahimi is an Assistant Professor in McGill University’s Department of Family Medicine, associate member of McGill’s Electrical and Computer Engineering Department, and affiliated scientist at the Lady Davis Institute for Medical Research of Jewish General Hospital.

Predictmedix will be working with Dr. Rahimi’s research group for its three industry verticals which include screening for infectious disease associated symptoms, screening for cannabis/alcohol impairment along with mental health screening technologies which are being developed by the company.

“We are extremely excited with the partnership with Dr. Samira Rahimi’s team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals.”, said Dr. Rahul Kushwah, COO of Predictmedix Inc.

Speaking of the partnership, Dr. Rahimi commented, “My team and I are looking forward to working with Predictmedix team. Predictmedix is one of the young and leading AI companies which aims to improve our healthcare system through innovative and cutting-edge digital health technologies.”

Click here to read the full article.

Categories
News

A COVID-19 Vaccine May Be Only 50% Effective. Is That Good Enough?

As we get closer to a COVID-19 vaccine, it’s exciting to imagine a day when the virus is gone. But a vaccine will not be a magic bullet. In fact, it may be only about 50% effective.

Dr. Anthony Fauci, chief of the National Institute of Health and Infectious Disease, has tried to set realistic expectations when discussing the importance of a vaccine. “We don’t know yet what the efficacy might be. We don’t know if it will be 50% or 60%,” Fauci said during a Brown University event in August.

“I’d like it to be 75% or more,” Fauci said, but he acknowledged that may not be realistic.

The Food and Drug Administration has said that once a vaccine is shown to be safe and at least 50% effective, it could be approved for use in the U.S.

So what does 50% efficacy mean?

Click here to continue reading the full article.

Categories
News

Health innovation: A cure for COVID-19 disruptions

Times are tough. COVID-19 has battered the healthcare ecosystem’s ability to heal, driving massive shortages in clinicians, hospital beds and medical supplies. How can organizations best weather this storm? Some healthcare players have a one-word solution: innovation.

Bets on a better future

A select group of health systems and hospitals are differentiating themselves from their peers, investing in the innovations they need to navigate the long-term uncertainties imposed by COVID-19. These organizations have pinpointed innovation as the best way to address the challenges of “the now, the next and the never normal” in the healthcare ecosystem. They recognize innovation can support care seekers, patients, clinicians, suppliers and the general public now, enable them to deal with the next threats and opportunities, and negotiate the chaotic shifts in cultural norms, values and behaviors posed by never normal long-term developments.

COVID-19 has brutally tested elements of the current healthcare value chain and found them lacking. Forward-thinking health players are using these insights to reimagine healthcare’s future in innovative ways. The following three healthcare organizations exemplify this trend of using near-term innovations to redefine their business and operating models for the era of COVID-19 and beyond.

Click here to continue reading the full article.